Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis (Q37297636)

19 August 2017

Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis (English)

1 reference

focal segmental glomerulosclerosis

19 August 2017

0 references

1 reference

1 reference

Gema Fernandez-Fresnedo

1

1 reference

19 August 2017

Alfonso Segarra

2

1 reference

19 August 2017

Ester González

3

1 reference

19 August 2017

Simona Alexandru

4

1 reference

19 August 2017

Ramon Delgado

5

1 reference

19 August 2017

Natalia Ramos

6

1 reference

19 August 2017

Jesús Egido

7

1 reference

19 August 2017

Manuel Praga

8

1 reference

19 August 2017

Trabajo de Enfermedades Glomerulares de la Sociedad Española de Nefrología (GLOSEN)

9

1 reference

19 August 2017

2 July 2009

1 reference

Clinical Journal of the American Society of Nephrology

19 August 2017

1 reference

19 August 2017

4

1 reference

19 August 2017

8

1 reference

19 August 2017

1317-1323

1 reference

Rapid remission of steroid and mycophenolate mofetil (mmf)-resistant minimal change nephrotic syndrome after rituximab therapy

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2723972

Drug insight: rituximab in renal disease and transplantation

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2723972

New insights into the pathogenesis and the therapy of recurrent focal glomerulosclerosis.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2723972

Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2723972

Truncation of C-mip (Tc-mip), a new proximal signaling protein, induces c-maf Th2 transcription factor and cytoskeleton reorganization

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2723972

B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2723972

A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2723972

IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2723972

Remission of steroid-resistant nephrotic syndrome due to focal and segmental glomerulosclerosis using rituximab

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2723972

Rituximab failed to improve nephrotic syndrome in renal transplant patients with recurrent focal segmental glomerulosclerosis

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2723972

Rituximab for refractory focal segmental glomerulosclerosis

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2723972

Rituximab treatment of idiopathic membranous nephropathy

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2723972

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2723972

Rituximab in idiopathic membranous nephropathy: a one-year prospective study

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2723972

Proteinuria and immunity--an overstated relationship?

2 September 2018

1 reference

12 December 2020

A glomerular permeability factor produced by human T cell hybridomas

1 reference

12 December 2020

Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome

1 reference

12 December 2020

Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis

1 reference

12 December 2020

Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome

1 reference

12 December 2020

Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment

1 reference

12 December 2020

Rituximab therapy for steroid-dependent minimal change nephrotic syndrome

1 reference

12 December 2020

Does rituximab treat recurrent focal segmental glomerulosclerosis post-renal transplantation?

1 reference

12 December 2020

Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximab

1 reference

12 December 2020

Treatment of focal segmental glomerular sclerosis with rituximab: 2 case reports

1 reference

12 December 2020

Abrogation of nephrotic proteinuria by rituximab treatment in a renal transplant patient with relapsed focal segmental glomerulosclerosis

1 reference

12 December 2020

Rituximab in patients with the steroid-resistant nephrotic syndrome

1 reference

12 December 2020

Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases

1 reference

12 December 2020

Identifiers

DOI

10.2215/CJN.00570109

1 reference

19 August 2017

1 reference

19 August 2017

PubMed publication ID

19578004

1 reference